Alignment Healthcare, Inc.
Alignment Healthcare, Inc. (ALHC) Stock Competitors & Peer Comparison
See (ALHC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALHC | $21.44 | +1.44% | 4.3B | -190.41 | -$0.11 | N/A |
| UNH | $367.14 | +3.44% | 321.9B | 26.81 | $13.23 | +2.50% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $81.07 | +4.02% | 100.5B | 56.39 | $1.39 | +3.40% |
| ELV | $364.52 | +5.73% | 77.4B | 15.08 | $23.62 | +1.93% |
| CI | $285.95 | +3.73% | 74.5B | 12.74 | $22.19 | +2.16% |
| HUM | $231.22 | +7.43% | 26.9B | 22.73 | $9.84 | +1.58% |
| CNC | $48.76 | +16.61% | 21.4B | -3.22 | -$13.53 | N/A |
| MOH | $188.41 | +7.08% | 9.3B | 48.09 | $3.73 | N/A |
| OSCR | $17.99 | +6.99% | 4.5B | -10.17 | -$1.69 | N/A |
Stock Comparison
ALHC vs UNH Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, UNH has a market cap of 321.9B. Regarding current trading prices, ALHC is priced at $21.44, while UNH trades at $367.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas UNH's P/E ratio is 26.81. In terms of profitability, ALHC's ROE is -0.00%, compared to UNH's ROE of +0.12%. Regarding short-term risk, ALHC is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check UNH's competition here
ALHC vs ANTM Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, ALHC is priced at $21.44, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, ALHC's ROE is -0.00%, compared to ANTM's ROE of +0.12%. Regarding short-term risk, ALHC is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check ANTM's competition here
ALHC vs CVS Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, CVS has a market cap of 100.5B. Regarding current trading prices, ALHC is priced at $21.44, while CVS trades at $81.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas CVS's P/E ratio is 56.39. In terms of profitability, ALHC's ROE is -0.00%, compared to CVS's ROE of +0.02%. Regarding short-term risk, ALHC is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CVS's competition here
ALHC vs ELV Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, ELV has a market cap of 77.4B. Regarding current trading prices, ALHC is priced at $21.44, while ELV trades at $364.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas ELV's P/E ratio is 15.08. In terms of profitability, ALHC's ROE is -0.00%, compared to ELV's ROE of +0.12%. Regarding short-term risk, ALHC is more volatile compared to ELV. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check ELV's competition here
ALHC vs CI Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, CI has a market cap of 74.5B. Regarding current trading prices, ALHC is priced at $21.44, while CI trades at $285.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas CI's P/E ratio is 12.74. In terms of profitability, ALHC's ROE is -0.00%, compared to CI's ROE of +0.15%. Regarding short-term risk, ALHC is more volatile compared to CI. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CI's competition here
ALHC vs HUM Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, HUM has a market cap of 26.9B. Regarding current trading prices, ALHC is priced at $21.44, while HUM trades at $231.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas HUM's P/E ratio is 22.73. In terms of profitability, ALHC's ROE is -0.00%, compared to HUM's ROE of +0.07%. Regarding short-term risk, ALHC is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check HUM's competition here
ALHC vs CNC Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, CNC has a market cap of 21.4B. Regarding current trading prices, ALHC is priced at $21.44, while CNC trades at $48.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas CNC's P/E ratio is -3.22. In terms of profitability, ALHC's ROE is -0.00%, compared to CNC's ROE of -0.28%. Regarding short-term risk, ALHC is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CNC's competition here
ALHC vs MOH Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, MOH has a market cap of 9.3B. Regarding current trading prices, ALHC is priced at $21.44, while MOH trades at $188.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas MOH's P/E ratio is 48.09. In terms of profitability, ALHC's ROE is -0.00%, compared to MOH's ROE of +0.04%. Regarding short-term risk, ALHC is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check MOH's competition here
ALHC vs OSCR Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, OSCR has a market cap of 4.5B. Regarding current trading prices, ALHC is priced at $21.44, while OSCR trades at $17.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas OSCR's P/E ratio is -10.17. In terms of profitability, ALHC's ROE is -0.00%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, ALHC is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check OSCR's competition here
ALHC vs CLOV Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, CLOV has a market cap of 1.3B. Regarding current trading prices, ALHC is priced at $21.44, while CLOV trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas CLOV's P/E ratio is -14.79. In terms of profitability, ALHC's ROE is -0.00%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, ALHC is more volatile compared to CLOV. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CLOV's competition here
ALHC vs BHG Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, ALHC is priced at $21.44, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, ALHC's ROE is -0.00%, compared to BHG's ROE of -0.70%. Regarding short-term risk, ALHC is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check BHG's competition here
ALHC vs CABR Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, CABR has a market cap of 17.5M. Regarding current trading prices, ALHC is priced at $21.44, while CABR trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas CABR's P/E ratio is -2.59. In terms of profitability, ALHC's ROE is -0.00%, compared to CABR's ROE of -3.00%. Regarding short-term risk, ALHC is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CABR's competition here
ALHC vs BMGL Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, BMGL has a market cap of 11.5M. Regarding current trading prices, ALHC is priced at $21.44, while BMGL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas BMGL's P/E ratio is -1.36. In terms of profitability, ALHC's ROE is -0.00%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, ALHC is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check BMGL's competition here
ALHC vs MRAI Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, MRAI has a market cap of 5.6M. Regarding current trading prices, ALHC is priced at $21.44, while MRAI trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas MRAI's P/E ratio is -0.11. In terms of profitability, ALHC's ROE is -0.00%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, ALHC is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check MRAI's competition here
ALHC vs NIVF Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, NIVF has a market cap of 1.1M. Regarding current trading prices, ALHC is priced at $21.44, while NIVF trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas NIVF's P/E ratio is 0.05. In terms of profitability, ALHC's ROE is -0.00%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, ALHC is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check NIVF's competition here
ALHC vs AET Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, AET has a market cap of 0. Regarding current trading prices, ALHC is priced at $21.44, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas AET's P/E ratio is N/A. In terms of profitability, ALHC's ROE is -0.00%, compared to AET's ROE of +0.11%. Regarding short-term risk, ALHC is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check AET's competition here
ALHC vs UAM Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, UAM has a market cap of 0. Regarding current trading prices, ALHC is priced at $21.44, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas UAM's P/E ratio is N/A. In terms of profitability, ALHC's ROE is -0.00%, compared to UAM's ROE of +0.17%. Regarding short-term risk, ALHC is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check UAM's competition here
ALHC vs MGLN Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, ALHC is priced at $21.44, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, ALHC's ROE is -0.00%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, ALHC is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check MGLN's competition here
ALHC vs GTS Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 4.3B. In comparison, GTS has a market cap of 0. Regarding current trading prices, ALHC is priced at $21.44, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -190.41, whereas GTS's P/E ratio is 10.41. In terms of profitability, ALHC's ROE is -0.00%, compared to GTS's ROE of +0.07%. Regarding short-term risk, ALHC is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check GTS's competition here